UPDATE: Cingulate (CING) - The CRL Lands, the Tripwire Arms
The scenario I called the “Dilution Trap made concrete” just stopped being hypothetical.
This morning Cingulate disclosed that the FDA issued a Complete Response Letter for CTx-1301. The agency flagged specific CMC information requests and — per management — raised no current concerns on clinical safety or efficacy. That framing is the only thing keeping the equity from a deeper hole today, and it is the thinnest of silver linings. Every red flag I’ve been writing about since the original deep dive — the CDMO’s Form 483, the “FDA may require additional time” tell buried in the Q1 10-Q, the Avondale CRL tripwire — has now converged into exactly the outcome the contracts were drafted around.
The Receipts
The CRL itself. Verbatim: “The FDA identified specific Chemistry, Manufacturing and Controls information requests in the CRL and did not raise any current concerns regarding the clinical safety or efficacy of CTx-1301. The Company expects a prompt resubmission to FDA of the remaining requested information addressing issues raised.”
The implication: The science survives — the trimodal 35/45/20 release profile, the pediatric ADHD-RS-5 effect sizes up to 1.185, the safety database — none of that is what killed the May 31 PDUFA. As I wrote in the deep dive, “the risk was never the science. It was always the factory and the balance sheet.” The factory lost.
The “nearly $30 million in cash” framing. Management’s lead reassurance in the PR is that they have ~$30M of cash and runway “to address the issues raised and execute on the resubmission process and continue pre-commercial activities into 2027.”
The implication: That number only exists because they ran the $100M AGP ATM, the Lincoln Park facility, the $12M Falcon Creek PIPE, and a Streeterville debt-for-equity exchange through Q1, taking the share count from 7.25M → 13.28M between Dec 31 and May 12. They walked into the CRL with cash; they did not walk in with an intact cap table. And every dollar of resubmission-related spend now competes with the Avondale redemption schedule.
The Avondale tripwire is now live. This is the part the press release does not mention. The 2025 Note ($6.57M principal, 9% interest) let Cingulate defer up to two monthly redemptions of up to $660K for 30 days each — “provided that the Company has not previously received a ‘complete response letter’ from the FDA.” That conditional just failed. The deferral right is extinguished. Avondale can demand cash on the scheduled redemption dates, and the Major/Minor Trigger Event clauses can inflate the outstanding balance by 15% per trigger, up to three times, with default interest accruing at 22% per annum.
The implication: The “toxic debt structures containing aggressive default triggers” I flagged in the original SELL case are no longer abstract risk language. They are an active line item on the cash runway management just told you stretches “into 2027.”
No resubmission timeline. The PR says “prompt” twice and gives no months, no Type A meeting date, no Class 1 vs. Class 2 resubmission designation.
The implication: A Class 2 resubmission (the typical CMC bucket) carries a 6-month FDA review clock from the date of resubmission — and that clock only starts after the CMC work at CoreRx/Bend is complete, the data package is rebuilt, and FDA accepts the response. A best-case “prompt” resubmission still likely pushes approval into mid-to-late 2027, on top of the cash drag from continued G&A, pre-commercial spend, and Avondale servicing.
The Scientific Reality Check
Nothing in today’s news changes the pharmacology. Dexmethylphenidate still works. The 35% immediate / 45% delayed at 3h / 20% booster at 7h release profile still solves the dopamine cliff problem the way I described it in the deep dive. If a larger CNS player wanted to acquire the asset and re-tool manufacturing at their own facility, the science transfers cleanly. The CRL is, narrowly, a manufacturing problem at a single contract manufacturer.
But “narrowly a CMC problem” is the most common CRL reason for 505(b)(2) drugs precisely because CMC problems are expensive and time-consuming to fix, not because they are minor. Fixing a CMC observation typically means new validation batches, new stability data, possibly new comparability studies — all gated by the same CDMO whose Form 483 started this story in February. The clinical risk was retired in 2024. The manufacturing risk was always the binding constraint, and it is still binding.
